Biodesix, Inc.
BDSX
$15.35
$0.130.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 25.56M | 28.76M | 21.77M | 20.02M | 17.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.56M | 28.76M | 21.77M | 20.02M | 17.96M |
| Cost of Revenue | 4.61M | 4.88M | 4.11M | 4.03M | 3.70M |
| Gross Profit | 20.95M | 23.88M | 17.66M | 15.99M | 14.26M |
| SG&A Expenses | 24.26M | 22.97M | 21.71M | 22.41M | 20.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.15M | 30.72M | 28.81M | 29.71M | 27.02M |
| Operating Income | -6.60M | -1.97M | -7.04M | -9.69M | -9.06M |
| Income Before Tax | -7.79M | -3.98M | -8.72M | -11.47M | -11.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.79M | -3.98M | -8.72M | -11.47M | -11.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.79M | -3.98M | -8.72M | -11.47M | -11.10M |
| EBIT | -6.60M | -1.97M | -7.04M | -9.69M | -9.06M |
| EBITDA | -5.20M | -579.00K | -5.64M | -8.26M | -7.62M |
| EPS Basic | -0.81 | -0.49 | -1.16 | -1.56 | -1.52 |
| Normalized Basic EPS | -0.53 | -0.31 | -0.73 | -0.98 | -0.94 |
| EPS Diluted | -0.81 | -0.49 | -1.16 | -1.56 | -1.52 |
| Normalized Diluted EPS | -0.53 | -0.31 | -0.73 | -0.98 | -0.94 |
| Average Basic Shares Outstanding | 9.66M | 8.07M | 7.50M | 7.33M | 7.30M |
| Average Diluted Shares Outstanding | 9.66M | 8.07M | 7.50M | 7.33M | 7.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |